Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis

Zhong, Jinglin; Huang, Danhui; Chen, Zi-Yu

doi:10.18632/oncotarget.18856

Cited by 211 publications

(245 citation statements)

References 34 publications

Supporting

Mentioning

229

Contrasting

Unclassified

Order By: Relevance

“…Recently, SII was developed as a new index based on circulating immune‐inflammatory cells, such as platelets, neutrophils and lymphocytes. The index has been widely reported to be associated with poor outcomes in patients with various cancers, 16‐18 indicating that it could be useful as a biomarker for future outcomes. In our study, the ACS group had higher SII score and WBC values, which reflect more severe inflammation.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, the systemic immune‐inflammation index (SII) was developed based on the platelet counts and NLR (SII, platelets count × neutrophil/lymphocyte ratio) to consider patients’ inflammatory and immune status simultaneously. A high SII was reported to be associated with poor outcomes in cancer patients, 16‐18 which indicates that the index could be used as a marker of prognostic value in various malignant diseases. To our interest, it has been mentioned that SII may also be associated with adverse outcomes in chronic heart failure 19 which suggests potential implications in cardiovascular disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Systemic immune‐inflammation index (SII) predicted clinical outcome in patients with coronary artery disease

Yang

Wu²,

Hsu³

et al. 2020

Eur J Clin Investigation

414

300

View full text Add to dashboard Cite

Background: This study examines the predictive value of a novel systemic immuneinflammation index (SII, platelet × neutrophil/lymphocyte ratio) in coronary artery disease (CAD) patients. Methods: A total of 5602 CAD patients who had undergone a percutaneous coronary intervention (PCI) were enrolled. They were divided into two groups by baseline SII score (high SII vs low SII) to analyse the relationship between SII groups and the long-term outcome. The primary outcomes were major cardiovascular events (MACE) which includes nonfatal myocardial infarction (MI), nonfatal stroke and cardiac death. Secondary outcomes included a composite of MACE and hospitalization for congestive heart failure. Results: An optimal SII cut-off point of 694.3 × 10 9 was identified for MACE in the CAD training cohort (n = 373) and then verified in the second larger CAD cohort (n = 5602). Univariate and multivariate analyses showed that a higher SII score (≥694.3) was independently associated with increased risk of developing cardiac death (HR: 2.02; 95% CI: 1.43-2.86), nonfatal MI (HR: 1.42; 95% CI: 1.09-1.85), nonfatal stroke (HR: 1.96; 95% CI: 1.28-2.99), MACE (HR: 1.65; 95% CI: 1.36-2.01) and total major events (HR: 1.53; 95% CI: 1.32-1.77). In addition, the SII significantly improved risk stratification of MI, cardiac death, heart failure, MACE and total major events than conventional risk factors in CAD patients by the significant increase in the C-index (P < .001) and reclassification risk categories by significant NRI (P < .05) and IDI (P < .05). Conclusions: SII had a better prediction of major cardiovascular events than traditional risk factors in CAD patients after coronary intervention. K E Y W O R D Scoronary artery disease, inflammation, percutaneous coronary intervention 2 of 11 | YANG et Al.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Systemic immune‐inflammation index (SII) predicted clinical outcome in patients with coronary artery disease

Yang

Wu²,

Hsu³

et al. 2020

Eur J Clin Investigation

414

300

View full text Add to dashboard Cite

show abstract

“…SII is a novel inflammation index, which was defined as follows: Plt × Neu / lymphocyte count . Recently, SII has been investigated as a prognostic marker in various malignancies, and it was reported as a more objective factor that represents the balance between the inflammatory and immune response of hosts compared with NLR and PLR . Lolli et al .…”

Section: Parameters Associated With Inflammationmentioning

confidence: 99%

“…75 SII is a novel inflammation index, which was defined as follows: Plt 9 Neu / lymphocyte count. 76 Recently, SII has been investigated as a prognostic marker in various malignancies, and it was reported as a more objective factor that represents the balance between the inflammatory and immune response of hosts compared with NLR and PLR. 76 Lolli et al showed that pretreatment SII and its changes at 6 weeks after starting systemic therapy are independent predictive and prognostic factors for patients with mRCC who underwent sunitinib treatment, and that the improvement of SII at 6 weeks was associated with a better prognosis.…”

Section: Inflammatory Indexes Consisting Of Peripheral Blood Cellsmentioning

confidence: 99%

“…76 Recently, SII has been investigated as a prognostic marker in various malignancies, and it was reported as a more objective factor that represents the balance between the inflammatory and immune response of hosts compared with NLR and PLR. 76 Lolli et al showed that pretreatment SII and its changes at 6 weeks after starting systemic therapy are independent predictive and prognostic factors for patients with mRCC who underwent sunitinib treatment, and that the improvement of SII at 6 weeks was associated with a better prognosis. 77 These inflammatory indexes are of special interest for mRCC, as well as their usefulness as predictive factors for the prognosis and therapeutic efficacy of other malignant diseases.…”

Section: Inflammatory Indexes Consisting Of Peripheral Blood Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Current status of prognostic factors in patients with metastatic renal cell carcinoma

et al. 2019

View full text Add to dashboard Cite

In recent years, the induction of novel agents, including molecular‐targeted agents and immune checkpoint inhibitors, have dramatically changed therapeutic options and their outcomes for metastatic renal cell carcinoma. Several prognostic models based on the data of patients with metastatic renal cell carcinoma treated with targeted agents or cytokine therapy have been useful in real clinical practice. Serum or peripheral blood markers related to inflammatory response have been reported to be associated with their prognosis or therapeutic efficacy. In addition to them, investigation for novel predictive factors that represent the efficacy of agents, the risk of adverse events and the prognosis are required for the advance of therapeutic strategies. The present review discusses the conventional prognostic models and clinical factors, and recent advances of the identification of some of the most promising molecules as novel biomarkers for metastatic renal cell carcinoma.

show abstract

Clinical and Laboratory Markers Associated With Relapse in Cutaneous Polyarteritis Nodosa

et al. 2018

View full text Add to dashboard Cite

In cutaneous polyarteritis nodosa (CPAN), less aggressive treatments can be selected, because CPAN is not associated with life-threatening or progressive outcomes. Although patients with a recurrent clinical course may require additional immunosuppressive therapies, no pretreatment factors associated with a worse prognosis in CPAN have been reported. OBJECTIVETo identify clinical or laboratory markers associated with relapse of CPAN.DESIGN, SETTING, AND PARTICIPANTS This retrospective case series was performed at a dermatology clinic of a tertiary referral center in Okayama, Japan, from October 1, 2001, through April 30, 2017. Of 30 patients identified with CPAN, the 21 with histopathologic evidence of disease were eligible and enrolled in the study. MAIN OUTCOMES AND MEASURESThe medical database was examined for sex, age at diagnosis, affected anatomical sites, type and extent of skin lesion, laboratory data, initial therapies, duration of follow-up, and current status. Relapse was defined as the first reoccurrence or new onset of cutaneous disease that required further escalation of treatment with prednisolone at a dosage of greater than 20 mg/d and/or add-on use of immunosuppressant therapy, more than 6 months after initial treatment. The pretreatment factors were statistically evaluated between the groups without and with relapse. RESULTSThe 21 patients included 5 males and 16 females with a median age of 49 years (range, 11-74 years) at diagnosis. The median follow-up was 42 months (range, 8-374 months). Pretreatment cutaneous ulcer was significantly associated with relapse between the 2 groups (0 of 11 in the nonrelapse group vs 4 of 10 in the relapse group; χ 2 1 = 4.67; P < .05). In the laboratory test results, significantly higher mean (SD) values were observed in the relapse group for C-reactive protein level (0.23 [2.00] vs 6.03 [3.10] mg/dL; standard error of the mean [SEM], 3.40 mg/dL; 95% CI, 0.01-10.8 mg/dL; P = .01), absolute neutrophil count (ANC) (3.4 × 10 3 /μL [1.1 × 10 3 /μL] vs 6.0 × 10 3 /μL [3.2 × 10 3 /μL]; SEM, 2.9 × 10 3 /μL; 95% CI, 1.9 × 10 3 /μL to 14.6 × 10 3 /μL; P = .001), neutrophil-to-lymphocyte ratio (1.4 [0.8] vs 2.8 [0.9]; SEM, 1.2; 95% CI, 1.1-4.9; P = .002), and systemic immune-inflammation index (5.

show abstract

Prognostic role of systemic immune-inflammation index in solid tumors: a systematic review and meta-analysis

Cited by 211 publications

References 34 publications

Systemic immune‐inflammation index (SII) predicted clinical outcome in patients with coronary artery disease

Systemic immune‐inflammation index (SII) predicted clinical outcome in patients with coronary artery disease

Current status of prognostic factors in patients with metastatic renal cell carcinoma

Clinical and Laboratory Markers Associated With Relapse in Cutaneous Polyarteritis Nodosa

Contact Info

Product

Resources

About